
NASDAQHealthcareMedical - Instruments & Supplies
最新資料
US$11.52
+US$0.29 · +2.58%
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.
前收盤價
US$11.52
+US$0.29 · +2.58%
盤中時間採用ET。市場資料可能有所延遲。
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.
日內區間
目前US$11.52
52週區間
目前US$11.52
盤中時間採用ET。市場資料可能有所延遲。
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.
日內區間
目前US$11.52
52週區間
目前US$11.52
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 3.2億 USD | 2.92億 USD | 3.04億 USD | 3.39億 USD | 3.16億 USD |
| 銷貨成本 | 1.45億 USD | 1.35億 USD | 1.49億 USD | 1.65億 USD | 1.5億 USD |
| 毛利 | 1.75億 USD | 1.58億 USD | 1.55億 USD | 1.74億 USD | 1.66億 USD |
| 研究與開發 | 2944.7萬 USD | 2622.2萬 USD | 3151.2萬 USD | 2988.3萬 USD | 3073.9萬 USD |
| 銷售、一般及管理費用 | 1.57億 USD | 1.45億 USD | 1.44億 USD | 1.44億 USD | 1.34億 USD |
| 營業費用 | 2.15億 USD | 1.98億 USD | 3.47億 USD | 2.25億 USD | 1.94億 USD |
| 利息收入 | — | 97.8萬 USD | 161.4萬 USD | — | — |
| 利息支出 | 29.9萬 USD | — | — | 270.2萬 USD | 68.8萬 USD |
| 折舊和攤銷 | 2295.5萬 USD | 2580萬 USD | 2771.2萬 USD | 3087.3萬 USD | 2934.9萬 USD |
| 營業利益 | −3992.7萬 USD | −3995.4萬 USD | −1.92億 USD | −5118.1萬 USD | −2847.1萬 USD |
| 淨利 | −3674.2萬 USD | −3399.3萬 USD | −1.84億 USD | −5244.2萬 USD | −2654.7萬 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動,並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1892.42萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1097.54萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF782.18萬0.01%954億 USD0.05%US$235+0.80%
Dimensional - US Small Cap ETFDFAS360.96萬0.01%338.69億 USD0.31%US$78.35+0.32%
Vanguard Russell 2000 ETFVTWO344.76萬0.02%180億 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA221.33萬0.01%218.24億 USD0.03%US$32.79+0.40%
Dimensional - US Core Equity 2 ETFDFAC220.28萬0.00%885.96億 USD0.21%US$45.33+0.49%
iShares U.S. Medical Devices ETFIHI209萬0.06%35.74億 USD0.37%US$51.74+1.25%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
Dimensional - US Small Cap ETFDFAS
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHA
Dimensional - US Core Equity 2 ETFDFAC
iShares U.S. Medical Devices ETFIHIAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。